This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen, the giant biotech company based in Thousand Oaks, saw its shares drop 2 percent to $149.23 on Sept. 3 after its rival Novartis launched a drug similar to Amgen’s that costs 15 percent less. Novartis’ Zarxio and Amgen’s Neupogen both help chemotherapy patients battle infections by increasing the production of white blood cells. The Read More →
Thousand Oaks-based biotech giant Amgen won U.S. approval for its powerful cholesterol-lowering drug Repatha for certain patients, making it the second in a new class of treatments to come to market, Bloomberg News reported Aug. 27. The Food and Drug Administration cleared Repatha for people with hard-to-treat levels of bad cholesterol, according to a statement Read More →
Thousand Oaks-based Amgen agreed to pay $71 million in a settlement with California, 47 other states and the District of Columbia because the biotech giant unlawfully promoted two drugs. According to a news release Aug. 18 from California Attorney General Kamala Harris, Amgen unlawfully promoted biologic medications Enbrel and Aranesp by “promoting Aranesp for dosing Read More →
Thousand Oaks-based Amgen Inc. posted second-quarter profit that topped analysts’ estimates, driven by higher sales and lower operating expenses. The biotech also raised its revenue and earnings forecast for the year. Profit excluding one-time items rose to $2.57 a share, while analysts had predicted $2.43 on average. Revenue increased 3.7 percent to $5.37 billion, the Read More →
The Food and Drug Administration approved Amgen’s Kyprolis for second-line treatments of multiple-myeloma on Friday. Thousand Oaks-based Amgen’s new treatment for multiple-myeloma could pay off big for the company now that the treatment can be accessed by more patients in the second line of treatments. Kyprolis was approved for third-line treatments in 2012. The FDA’s Read More →
Thousand Oaks-based Amgen announced Thursday that it submitted data comparing its new multiple-myeloma drug against a rival to the Food and Drug Administration. Kyprolis is Amgen’s new treatment for multiple-myeloma, which is a form of blood cancer that forms in plasma cells and typically grows in bone marrow. The drug was approved for third-line treatments Read More →
